While the exact mechanisms by which Ozempic may cause vision damage are not fully understood, several theories have emerged: Rapid blood sugar changes affecting retinal blood vessels Direct effects of the medication on eye structures Indirect effects due to significant weight loss Establishing causation in pharmaceutical cases is a complex challenge, requiring clear evidence linking the medication to the injury
On December 19, 2025, Eli Lilly announced that retatrutide produced 28.7% body weight loss in the Phase 3 TRIUMPH-4 trial
Left untreated, the damage may result in vision loss
Most studies evaluated oral supplements, not patches, and even the oral supplements showed questionable results, making it extremely unlikely that patches would have any meaningful effects on weight loss in humans
It must not be used to guide prescribing decisions outside of a formally approved trial
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis